Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Daratumumab (Primary) ; Autologous stem cell therapy; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Feb 2025 Planned End Date changed from 1 Dec 2025 to 18 Dec 2025.
- 21 Feb 2025 Planned primary completion date changed from 1 Dec 2025 to 18 Dec 2025.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition